行情

BHVN

BHVN

Biohaven Pharma
NYSE

实时行情|Nasdaq Last Sale

45.34
-0.54
-1.18%
盘前: 45.00 -0.34 -0.75% 08:53 02/24 EST
开盘
45.80
昨收
45.88
最高
45.91
最低
44.78
成交量
187
成交额
--
52周最高
67.86
52周最低
36.69
市值
25.87亿
市盈率(TTM)
-4.7957
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BHVN价格均价为71.33,最高价位100.00,最低价为50.00。

EPS

BHVN 新闻

更多
  • Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
  • PR Newswire · 02/14 12:33
  • Biohaven Pharmaceutical Option Alert: Apr 17 $55 Calls Sweep (2) near the midpoint: 4997 @ $6.05 vs 307 OI; Earnings 2/27 After Close [est] Ref=$45.88
  • Benzinga · 02/13 20:19
  • Should Investors Buy Biohaven's Stock Now?
  • MotleyFool.com · 02/13 15:00
  • 3 Beaten-Down Biotech Stocks With +50% Upside Potential
  • TipRanks · 02/11 16:27

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.55%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

BHVN 简况

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
展开

微牛提供Biohaven Pharmaceutical Holding Co Ltd(NYSE-BHVN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BHVN股票新闻,以帮助您做出投资决策。